Nearly six years after Ichnos Sciences Inc. launched operations, a subsidiary of the now-named Ichnos Glenmark Innovation ...

The U.K.’s National Institute for Health and Care Excellence (NICE) recommends the use of pulsed field ablation as an option ...

At first blush, the brain’s extracellular matrix (ECM) seems like the opposite of synaptic plasticity. Plasticity is the ...

Researchers from IMEC, the Netherlands’ OnePlanet Research Center in Wageningen, filed for protection of an inexpensive, ...

The U.S. FDA noted in a series of Federal Register declarations that several device makers are working with the Patent and ...

Multiple sclerosis (MS) is an immune-mediated inflammatory disease characterized by demyelination and degeneration in the ...

Sensorium Therapeutics Inc. has reported that the U.S. FDA has cleared the IND application for SNTX-2643 (SENS-01), its lead ...

Eluciderm Inc. has received clearance from the U.S. FDA for its IND to conduct a phase I/IIa open-label study evaluating the ...

Merck & Co. Inc. has strengthened its cardiopulmonary pipeline with its $10 billion acquisition of London-based-Verona Pharma plc. The deal brings Merck Ohtuvayre (ensifentrine) for chronic ...

The next FDA device user fee agreement is formally in negotiations but a recent agency report shows device makers are increasingly keen to interact with FDA reviewers. This is a fact that may make it ...

Latvian Institute of Organic Synthesis has identified subtilisin-like protease 1 (PfSUB1) (Plasmodium falciparum) inhibitors reported to be useful for the treatment of malaria.

Rhythm Pharmaceuticals Inc. will be sitting down with regulators in the U.S. and Europe to discuss phase III plans in the wake of positive phase II data from the study testing bivamelagon (formerly ...